Loading…

Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement

To describe the clinical histories and management of adults with type 2 diabetes who were not reaching their target glycated hemoglobin (A1C) levels and to identify barriers to achieving therapeutic goals. Practice assessment surveys and practice audits were completed by 88 primary care physicians (...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal of diabetes 2019-08, Vol.43 (6), p.384-391
Main Authors: Leiter, Lawrence A., Cheng, Alice Y.Y., Ekoé, Jean-Marie, Goldenberg, Ronald M., Harris, Stewart B., Hramiak, Irene M., Khunti, Kamlesh, Lin, Peter J., Richard, Jean-François, Senior, Peter A., Yale, Jean-François, Goldin, Lianne, Tan, Mary K., Langer, Anatoly
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c356t-20c492fdfc100a1660f028f0c0a3e977cabf5d0ad7fca931cb2068fb6aa661663
cites cdi_FETCH-LOGICAL-c356t-20c492fdfc100a1660f028f0c0a3e977cabf5d0ad7fca931cb2068fb6aa661663
container_end_page 391
container_issue 6
container_start_page 384
container_title Canadian journal of diabetes
container_volume 43
creator Leiter, Lawrence A.
Cheng, Alice Y.Y.
Ekoé, Jean-Marie
Goldenberg, Ronald M.
Harris, Stewart B.
Hramiak, Irene M.
Khunti, Kamlesh
Lin, Peter J.
Richard, Jean-François
Senior, Peter A.
Yale, Jean-François
Goldin, Lianne
Tan, Mary K.
Langer, Anatoly
description To describe the clinical histories and management of adults with type 2 diabetes who were not reaching their target glycated hemoglobin (A1C) levels and to identify barriers to achieving therapeutic goals. Practice assessment surveys and practice audits were completed by 88 primary care physicians (PCPs) in the Diabetes Mellitus Assessment of Clinical managemenT In ONtario (DM-ACTION) program and by 56 diabetes specialists in the Diabetes Mellitus IMproving PAtient Care in our communiTies (DM-IMPACT) program. The DM-ACTION audit analyzed data from 1,173 adults with A1C levels ≥7.3% who were not prescribed insulin; the DM-IMPACT audit included 135 individuals with similar characteristics. Most PCPs (92%) and specialists (88%) stated that they typically recommend A1C levels of ≤7.0%; more than 90% indicated that they adjusted antihyperglycemic therapy within 3 months if suboptimal A1C targets endured. Among the DM-ACTION patients, the median A1C level was 7.8%; the median time between the last 2 A1C tests was 5 months; 58% were taking ≤2 noninsulin antihyperglycemic agents; and adjustment of glucose-lowering therapy was noted for only 56%. The corresponding values for the DM-IMPACT patients were 8.0%, 4 months, 43% and 68%, respectively. PCPs and specialists attributed patients' factors and patients' adherence as primary causes of poor achievement of guideline-recommended targets. PCPs perceived patients' factors as the predominant barrier to optimizing care, but the specialists believed that therapeutic inertia stems from a wide range and a varied combination of patient-centric factors. Type 2 diabetes remains a health-care challenge in Canada and globally. Primary care physicians and specialists attributed patients' factors as principal obstacles to optimal diabetes management. However, physician-associated therapeutic inertia may also be an important barrier to unmet therapeutic goals. Décrire les antécédents cliniques et la prise en charge des adultes atteints du diabète de type 2 qui n'avaient pas atteint leurs valeurs cibles d'hémoglobine glyquée (A1c) et déterminer les obstacles à l'atteinte des objectifs thérapeutiques. Quatre-vingt-huit médecins en soins de santé primaires (MSSP) du programme DM-ACTION (Diabetes Mellitus Assessment of Clinical managemenT In ONtario) et 56 spécialistes du diabète du programme DM-IMPACT (Diabetes Mellitus IMproving PAtient Care in our communiTies) ont rempli les enquêtes d'évaluation des pratiques et les audits de pra
doi_str_mv 10.1016/j.jcjd.2018.10.005
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2157656933</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1499267118303708</els_id><sourcerecordid>2157656933</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-20c492fdfc100a1660f028f0c0a3e977cabf5d0ad7fca931cb2068fb6aa661663</originalsourceid><addsrcrecordid>eNp9kMGO0zAQhi0EYsvCC3BAPnJJGTu1kyAuVRe6K1VCgkUcLcces46cuMTuSn17HHXhyGk0M9_8lj9C3jJYM2Dyw7AezGDXHFhbBmsA8YyseC14VbcbeE5WbNN1FZcNuyKvUhoKAA3rXpKrGoTYdK1YkbgPZ6MzWnqLY_wVYu8nesBHDHQfdaBb8-BLN-KUadls7SnkRH_6_EDvz0eknN543WPGtKx3etJWf6Tfsw-BfotxpC7O9G48zvES8pq8cDokfPNUr8mPL5_vd7fV4ev-brc9VKYWMlcczKbjzjrDADSTEhzw1oEBXWPXNEb3TljQtnFGdzUzPQfZul5qLWXB62vy_pJbXv59wpTV6JPBEPSE8ZQUZ6KRQnZ1XVB-Qc0cU5rRqePsRz2fFQO1iFaDWkSrRfQyKx7L0bun_FM_ov138tdsAT5dACy_fPQ4q2Q8Tgatn9FkZaP_X_4fAhaO2g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2157656933</pqid></control><display><type>article</type><title>Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement</title><source>ScienceDirect Freedom Collection</source><creator>Leiter, Lawrence A. ; Cheng, Alice Y.Y. ; Ekoé, Jean-Marie ; Goldenberg, Ronald M. ; Harris, Stewart B. ; Hramiak, Irene M. ; Khunti, Kamlesh ; Lin, Peter J. ; Richard, Jean-François ; Senior, Peter A. ; Yale, Jean-François ; Goldin, Lianne ; Tan, Mary K. ; Langer, Anatoly</creator><creatorcontrib>Leiter, Lawrence A. ; Cheng, Alice Y.Y. ; Ekoé, Jean-Marie ; Goldenberg, Ronald M. ; Harris, Stewart B. ; Hramiak, Irene M. ; Khunti, Kamlesh ; Lin, Peter J. ; Richard, Jean-François ; Senior, Peter A. ; Yale, Jean-François ; Goldin, Lianne ; Tan, Mary K. ; Langer, Anatoly</creatorcontrib><description>To describe the clinical histories and management of adults with type 2 diabetes who were not reaching their target glycated hemoglobin (A1C) levels and to identify barriers to achieving therapeutic goals. Practice assessment surveys and practice audits were completed by 88 primary care physicians (PCPs) in the Diabetes Mellitus Assessment of Clinical managemenT In ONtario (DM-ACTION) program and by 56 diabetes specialists in the Diabetes Mellitus IMproving PAtient Care in our communiTies (DM-IMPACT) program. The DM-ACTION audit analyzed data from 1,173 adults with A1C levels ≥7.3% who were not prescribed insulin; the DM-IMPACT audit included 135 individuals with similar characteristics. Most PCPs (92%) and specialists (88%) stated that they typically recommend A1C levels of ≤7.0%; more than 90% indicated that they adjusted antihyperglycemic therapy within 3 months if suboptimal A1C targets endured. Among the DM-ACTION patients, the median A1C level was 7.8%; the median time between the last 2 A1C tests was 5 months; 58% were taking ≤2 noninsulin antihyperglycemic agents; and adjustment of glucose-lowering therapy was noted for only 56%. The corresponding values for the DM-IMPACT patients were 8.0%, 4 months, 43% and 68%, respectively. PCPs and specialists attributed patients' factors and patients' adherence as primary causes of poor achievement of guideline-recommended targets. PCPs perceived patients' factors as the predominant barrier to optimizing care, but the specialists believed that therapeutic inertia stems from a wide range and a varied combination of patient-centric factors. Type 2 diabetes remains a health-care challenge in Canada and globally. Primary care physicians and specialists attributed patients' factors as principal obstacles to optimal diabetes management. However, physician-associated therapeutic inertia may also be an important barrier to unmet therapeutic goals. Décrire les antécédents cliniques et la prise en charge des adultes atteints du diabète de type 2 qui n'avaient pas atteint leurs valeurs cibles d'hémoglobine glyquée (A1c) et déterminer les obstacles à l'atteinte des objectifs thérapeutiques. Quatre-vingt-huit médecins en soins de santé primaires (MSSP) du programme DM-ACTION (Diabetes Mellitus Assessment of Clinical managemenT In ONtario) et 56 spécialistes du diabète du programme DM-IMPACT (Diabetes Mellitus IMproving PAtient Care in our communiTies) ont rempli les enquêtes d'évaluation des pratiques et les audits de pratique. L'audit du DM-ACTION a permis d'analyser les données de 1173 adultes qui avaient des concentrations d'A1c ≥ 7,3 % et qui ne s'étaient pas fait prescrire d'insuline; l'audit du DM-IMPACT portait sur 135 individus qui avaient des caractéristiques similaires. La plupart des MSSP (92 %) et des spécialistes (88 %) ont déclaré avoir habituellement recommandé des concentrations d'A1C ≤ 7,0 %; plus de 90 % ont indiqué avoir ajusté le traitement antihyperglycémique dans les 3 mois si les valeurs cibles sous-optimales de l'A1c s'étaient maintenues. Parmi les patients du DM-ACTION, la concentration médiane d'A1c était de 7,8 %; le temps médian entre les 2 dernières épreuves d'A1c était de 5 mois; 58 % prenaient ≤2 antihyperglycémiants non insuliniques; l'ajustement du traitement hypoglycémiant a été noté chez seulement 56 % des individus. Les valeurs correspondantes chez les patients du DM-IMPACT étaient respectivement de 8,0 %, de 4 mois, de 43 % et de 68 %. Les MSSP et les spécialistes ont considéré que les facteurs liés aux patients et à l'observance des patients étaient les principales causes de la faible atteinte des valeurs cibles recommandées par les lignes directrices. Les MSSP ont perçu les facteurs liés aux patients comme l'obstacle le plus important à l'optimisation des soins, mais les spécialistes ont cru que l'inertie thérapeutique découlait d'un large éventail et d'une combinaison variée de facteurs axés sur le patient. Le diabète de type 2 reste un problème important pour les soins de santé au Canada et dans le monde entier. Les MSSP et les spécialistes ont considéré que les principaux obstacles à la prise en charge optimale du diabète étaient attribuables aux facteurs liés aux patients. Toutefois, l'inertie thérapeutique des médecins peut également être un obstacle important à la non-atteinte des objectifs thérapeutiques.</description><identifier>ISSN: 1499-2671</identifier><identifier>EISSN: 2352-3840</identifier><identifier>DOI: 10.1016/j.jcjd.2018.10.005</identifier><identifier>PMID: 30554985</identifier><language>eng</language><publisher>Canada: Elsevier Inc</publisher><subject>Adult ; Biomarkers - analysis ; Blood Glucose - analysis ; Diabetes Mellitus, Type 2 - metabolism ; Diabetes Mellitus, Type 2 - prevention &amp; control ; diabète de type 2 ; Disease Management ; Female ; Follow-Up Studies ; Glycated Hemoglobin A - analysis ; Humans ; Hypoglycemic Agents - therapeutic use ; inertie thérapeutique ; Male ; Medication Adherence - statistics &amp; numerical data ; Middle Aged ; Needs Assessment ; Patient Care - methods ; Patient Care - standards ; Physicians, Primary Care - standards ; Practice Guidelines as Topic - standards ; primary care ; Prognosis ; soins de santé primaires ; specialist ; Specialization - statistics &amp; numerical data ; spécialiste ; Surveys and Questionnaires ; therapeutic inertia ; type 2 diabetes</subject><ispartof>Canadian journal of diabetes, 2019-08, Vol.43 (6), p.384-391</ispartof><rights>2018 Canadian Diabetes Association</rights><rights>Copyright © 2018 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-20c492fdfc100a1660f028f0c0a3e977cabf5d0ad7fca931cb2068fb6aa661663</citedby><cites>FETCH-LOGICAL-c356t-20c492fdfc100a1660f028f0c0a3e977cabf5d0ad7fca931cb2068fb6aa661663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30554985$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leiter, Lawrence A.</creatorcontrib><creatorcontrib>Cheng, Alice Y.Y.</creatorcontrib><creatorcontrib>Ekoé, Jean-Marie</creatorcontrib><creatorcontrib>Goldenberg, Ronald M.</creatorcontrib><creatorcontrib>Harris, Stewart B.</creatorcontrib><creatorcontrib>Hramiak, Irene M.</creatorcontrib><creatorcontrib>Khunti, Kamlesh</creatorcontrib><creatorcontrib>Lin, Peter J.</creatorcontrib><creatorcontrib>Richard, Jean-François</creatorcontrib><creatorcontrib>Senior, Peter A.</creatorcontrib><creatorcontrib>Yale, Jean-François</creatorcontrib><creatorcontrib>Goldin, Lianne</creatorcontrib><creatorcontrib>Tan, Mary K.</creatorcontrib><creatorcontrib>Langer, Anatoly</creatorcontrib><title>Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement</title><title>Canadian journal of diabetes</title><addtitle>Can J Diabetes</addtitle><description>To describe the clinical histories and management of adults with type 2 diabetes who were not reaching their target glycated hemoglobin (A1C) levels and to identify barriers to achieving therapeutic goals. Practice assessment surveys and practice audits were completed by 88 primary care physicians (PCPs) in the Diabetes Mellitus Assessment of Clinical managemenT In ONtario (DM-ACTION) program and by 56 diabetes specialists in the Diabetes Mellitus IMproving PAtient Care in our communiTies (DM-IMPACT) program. The DM-ACTION audit analyzed data from 1,173 adults with A1C levels ≥7.3% who were not prescribed insulin; the DM-IMPACT audit included 135 individuals with similar characteristics. Most PCPs (92%) and specialists (88%) stated that they typically recommend A1C levels of ≤7.0%; more than 90% indicated that they adjusted antihyperglycemic therapy within 3 months if suboptimal A1C targets endured. Among the DM-ACTION patients, the median A1C level was 7.8%; the median time between the last 2 A1C tests was 5 months; 58% were taking ≤2 noninsulin antihyperglycemic agents; and adjustment of glucose-lowering therapy was noted for only 56%. The corresponding values for the DM-IMPACT patients were 8.0%, 4 months, 43% and 68%, respectively. PCPs and specialists attributed patients' factors and patients' adherence as primary causes of poor achievement of guideline-recommended targets. PCPs perceived patients' factors as the predominant barrier to optimizing care, but the specialists believed that therapeutic inertia stems from a wide range and a varied combination of patient-centric factors. Type 2 diabetes remains a health-care challenge in Canada and globally. Primary care physicians and specialists attributed patients' factors as principal obstacles to optimal diabetes management. However, physician-associated therapeutic inertia may also be an important barrier to unmet therapeutic goals. Décrire les antécédents cliniques et la prise en charge des adultes atteints du diabète de type 2 qui n'avaient pas atteint leurs valeurs cibles d'hémoglobine glyquée (A1c) et déterminer les obstacles à l'atteinte des objectifs thérapeutiques. Quatre-vingt-huit médecins en soins de santé primaires (MSSP) du programme DM-ACTION (Diabetes Mellitus Assessment of Clinical managemenT In ONtario) et 56 spécialistes du diabète du programme DM-IMPACT (Diabetes Mellitus IMproving PAtient Care in our communiTies) ont rempli les enquêtes d'évaluation des pratiques et les audits de pratique. L'audit du DM-ACTION a permis d'analyser les données de 1173 adultes qui avaient des concentrations d'A1c ≥ 7,3 % et qui ne s'étaient pas fait prescrire d'insuline; l'audit du DM-IMPACT portait sur 135 individus qui avaient des caractéristiques similaires. La plupart des MSSP (92 %) et des spécialistes (88 %) ont déclaré avoir habituellement recommandé des concentrations d'A1C ≤ 7,0 %; plus de 90 % ont indiqué avoir ajusté le traitement antihyperglycémique dans les 3 mois si les valeurs cibles sous-optimales de l'A1c s'étaient maintenues. Parmi les patients du DM-ACTION, la concentration médiane d'A1c était de 7,8 %; le temps médian entre les 2 dernières épreuves d'A1c était de 5 mois; 58 % prenaient ≤2 antihyperglycémiants non insuliniques; l'ajustement du traitement hypoglycémiant a été noté chez seulement 56 % des individus. Les valeurs correspondantes chez les patients du DM-IMPACT étaient respectivement de 8,0 %, de 4 mois, de 43 % et de 68 %. Les MSSP et les spécialistes ont considéré que les facteurs liés aux patients et à l'observance des patients étaient les principales causes de la faible atteinte des valeurs cibles recommandées par les lignes directrices. Les MSSP ont perçu les facteurs liés aux patients comme l'obstacle le plus important à l'optimisation des soins, mais les spécialistes ont cru que l'inertie thérapeutique découlait d'un large éventail et d'une combinaison variée de facteurs axés sur le patient. Le diabète de type 2 reste un problème important pour les soins de santé au Canada et dans le monde entier. Les MSSP et les spécialistes ont considéré que les principaux obstacles à la prise en charge optimale du diabète étaient attribuables aux facteurs liés aux patients. Toutefois, l'inertie thérapeutique des médecins peut également être un obstacle important à la non-atteinte des objectifs thérapeutiques.</description><subject>Adult</subject><subject>Biomarkers - analysis</subject><subject>Blood Glucose - analysis</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Diabetes Mellitus, Type 2 - prevention &amp; control</subject><subject>diabète de type 2</subject><subject>Disease Management</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>inertie thérapeutique</subject><subject>Male</subject><subject>Medication Adherence - statistics &amp; numerical data</subject><subject>Middle Aged</subject><subject>Needs Assessment</subject><subject>Patient Care - methods</subject><subject>Patient Care - standards</subject><subject>Physicians, Primary Care - standards</subject><subject>Practice Guidelines as Topic - standards</subject><subject>primary care</subject><subject>Prognosis</subject><subject>soins de santé primaires</subject><subject>specialist</subject><subject>Specialization - statistics &amp; numerical data</subject><subject>spécialiste</subject><subject>Surveys and Questionnaires</subject><subject>therapeutic inertia</subject><subject>type 2 diabetes</subject><issn>1499-2671</issn><issn>2352-3840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kMGO0zAQhi0EYsvCC3BAPnJJGTu1kyAuVRe6K1VCgkUcLcces46cuMTuSn17HHXhyGk0M9_8lj9C3jJYM2Dyw7AezGDXHFhbBmsA8YyseC14VbcbeE5WbNN1FZcNuyKvUhoKAA3rXpKrGoTYdK1YkbgPZ6MzWnqLY_wVYu8nesBHDHQfdaBb8-BLN-KUadls7SnkRH_6_EDvz0eknN543WPGtKx3etJWf6Tfsw-BfotxpC7O9G48zvES8pq8cDokfPNUr8mPL5_vd7fV4ev-brc9VKYWMlcczKbjzjrDADSTEhzw1oEBXWPXNEb3TljQtnFGdzUzPQfZul5qLWXB62vy_pJbXv59wpTV6JPBEPSE8ZQUZ6KRQnZ1XVB-Qc0cU5rRqePsRz2fFQO1iFaDWkSrRfQyKx7L0bun_FM_ov138tdsAT5dACy_fPQ4q2Q8Tgatn9FkZaP_X_4fAhaO2g</recordid><startdate>201908</startdate><enddate>201908</enddate><creator>Leiter, Lawrence A.</creator><creator>Cheng, Alice Y.Y.</creator><creator>Ekoé, Jean-Marie</creator><creator>Goldenberg, Ronald M.</creator><creator>Harris, Stewart B.</creator><creator>Hramiak, Irene M.</creator><creator>Khunti, Kamlesh</creator><creator>Lin, Peter J.</creator><creator>Richard, Jean-François</creator><creator>Senior, Peter A.</creator><creator>Yale, Jean-François</creator><creator>Goldin, Lianne</creator><creator>Tan, Mary K.</creator><creator>Langer, Anatoly</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201908</creationdate><title>Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement</title><author>Leiter, Lawrence A. ; Cheng, Alice Y.Y. ; Ekoé, Jean-Marie ; Goldenberg, Ronald M. ; Harris, Stewart B. ; Hramiak, Irene M. ; Khunti, Kamlesh ; Lin, Peter J. ; Richard, Jean-François ; Senior, Peter A. ; Yale, Jean-François ; Goldin, Lianne ; Tan, Mary K. ; Langer, Anatoly</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-20c492fdfc100a1660f028f0c0a3e977cabf5d0ad7fca931cb2068fb6aa661663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Biomarkers - analysis</topic><topic>Blood Glucose - analysis</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Diabetes Mellitus, Type 2 - prevention &amp; control</topic><topic>diabète de type 2</topic><topic>Disease Management</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>inertie thérapeutique</topic><topic>Male</topic><topic>Medication Adherence - statistics &amp; numerical data</topic><topic>Middle Aged</topic><topic>Needs Assessment</topic><topic>Patient Care - methods</topic><topic>Patient Care - standards</topic><topic>Physicians, Primary Care - standards</topic><topic>Practice Guidelines as Topic - standards</topic><topic>primary care</topic><topic>Prognosis</topic><topic>soins de santé primaires</topic><topic>specialist</topic><topic>Specialization - statistics &amp; numerical data</topic><topic>spécialiste</topic><topic>Surveys and Questionnaires</topic><topic>therapeutic inertia</topic><topic>type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leiter, Lawrence A.</creatorcontrib><creatorcontrib>Cheng, Alice Y.Y.</creatorcontrib><creatorcontrib>Ekoé, Jean-Marie</creatorcontrib><creatorcontrib>Goldenberg, Ronald M.</creatorcontrib><creatorcontrib>Harris, Stewart B.</creatorcontrib><creatorcontrib>Hramiak, Irene M.</creatorcontrib><creatorcontrib>Khunti, Kamlesh</creatorcontrib><creatorcontrib>Lin, Peter J.</creatorcontrib><creatorcontrib>Richard, Jean-François</creatorcontrib><creatorcontrib>Senior, Peter A.</creatorcontrib><creatorcontrib>Yale, Jean-François</creatorcontrib><creatorcontrib>Goldin, Lianne</creatorcontrib><creatorcontrib>Tan, Mary K.</creatorcontrib><creatorcontrib>Langer, Anatoly</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Canadian journal of diabetes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leiter, Lawrence A.</au><au>Cheng, Alice Y.Y.</au><au>Ekoé, Jean-Marie</au><au>Goldenberg, Ronald M.</au><au>Harris, Stewart B.</au><au>Hramiak, Irene M.</au><au>Khunti, Kamlesh</au><au>Lin, Peter J.</au><au>Richard, Jean-François</au><au>Senior, Peter A.</au><au>Yale, Jean-François</au><au>Goldin, Lianne</au><au>Tan, Mary K.</au><au>Langer, Anatoly</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement</atitle><jtitle>Canadian journal of diabetes</jtitle><addtitle>Can J Diabetes</addtitle><date>2019-08</date><risdate>2019</risdate><volume>43</volume><issue>6</issue><spage>384</spage><epage>391</epage><pages>384-391</pages><issn>1499-2671</issn><eissn>2352-3840</eissn><abstract>To describe the clinical histories and management of adults with type 2 diabetes who were not reaching their target glycated hemoglobin (A1C) levels and to identify barriers to achieving therapeutic goals. Practice assessment surveys and practice audits were completed by 88 primary care physicians (PCPs) in the Diabetes Mellitus Assessment of Clinical managemenT In ONtario (DM-ACTION) program and by 56 diabetes specialists in the Diabetes Mellitus IMproving PAtient Care in our communiTies (DM-IMPACT) program. The DM-ACTION audit analyzed data from 1,173 adults with A1C levels ≥7.3% who were not prescribed insulin; the DM-IMPACT audit included 135 individuals with similar characteristics. Most PCPs (92%) and specialists (88%) stated that they typically recommend A1C levels of ≤7.0%; more than 90% indicated that they adjusted antihyperglycemic therapy within 3 months if suboptimal A1C targets endured. Among the DM-ACTION patients, the median A1C level was 7.8%; the median time between the last 2 A1C tests was 5 months; 58% were taking ≤2 noninsulin antihyperglycemic agents; and adjustment of glucose-lowering therapy was noted for only 56%. The corresponding values for the DM-IMPACT patients were 8.0%, 4 months, 43% and 68%, respectively. PCPs and specialists attributed patients' factors and patients' adherence as primary causes of poor achievement of guideline-recommended targets. PCPs perceived patients' factors as the predominant barrier to optimizing care, but the specialists believed that therapeutic inertia stems from a wide range and a varied combination of patient-centric factors. Type 2 diabetes remains a health-care challenge in Canada and globally. Primary care physicians and specialists attributed patients' factors as principal obstacles to optimal diabetes management. However, physician-associated therapeutic inertia may also be an important barrier to unmet therapeutic goals. Décrire les antécédents cliniques et la prise en charge des adultes atteints du diabète de type 2 qui n'avaient pas atteint leurs valeurs cibles d'hémoglobine glyquée (A1c) et déterminer les obstacles à l'atteinte des objectifs thérapeutiques. Quatre-vingt-huit médecins en soins de santé primaires (MSSP) du programme DM-ACTION (Diabetes Mellitus Assessment of Clinical managemenT In ONtario) et 56 spécialistes du diabète du programme DM-IMPACT (Diabetes Mellitus IMproving PAtient Care in our communiTies) ont rempli les enquêtes d'évaluation des pratiques et les audits de pratique. L'audit du DM-ACTION a permis d'analyser les données de 1173 adultes qui avaient des concentrations d'A1c ≥ 7,3 % et qui ne s'étaient pas fait prescrire d'insuline; l'audit du DM-IMPACT portait sur 135 individus qui avaient des caractéristiques similaires. La plupart des MSSP (92 %) et des spécialistes (88 %) ont déclaré avoir habituellement recommandé des concentrations d'A1C ≤ 7,0 %; plus de 90 % ont indiqué avoir ajusté le traitement antihyperglycémique dans les 3 mois si les valeurs cibles sous-optimales de l'A1c s'étaient maintenues. Parmi les patients du DM-ACTION, la concentration médiane d'A1c était de 7,8 %; le temps médian entre les 2 dernières épreuves d'A1c était de 5 mois; 58 % prenaient ≤2 antihyperglycémiants non insuliniques; l'ajustement du traitement hypoglycémiant a été noté chez seulement 56 % des individus. Les valeurs correspondantes chez les patients du DM-IMPACT étaient respectivement de 8,0 %, de 4 mois, de 43 % et de 68 %. Les MSSP et les spécialistes ont considéré que les facteurs liés aux patients et à l'observance des patients étaient les principales causes de la faible atteinte des valeurs cibles recommandées par les lignes directrices. Les MSSP ont perçu les facteurs liés aux patients comme l'obstacle le plus important à l'optimisation des soins, mais les spécialistes ont cru que l'inertie thérapeutique découlait d'un large éventail et d'une combinaison variée de facteurs axés sur le patient. Le diabète de type 2 reste un problème important pour les soins de santé au Canada et dans le monde entier. Les MSSP et les spécialistes ont considéré que les principaux obstacles à la prise en charge optimale du diabète étaient attribuables aux facteurs liés aux patients. Toutefois, l'inertie thérapeutique des médecins peut également être un obstacle important à la non-atteinte des objectifs thérapeutiques.</abstract><cop>Canada</cop><pub>Elsevier Inc</pub><pmid>30554985</pmid><doi>10.1016/j.jcjd.2018.10.005</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1499-2671
ispartof Canadian journal of diabetes, 2019-08, Vol.43 (6), p.384-391
issn 1499-2671
2352-3840
language eng
recordid cdi_proquest_miscellaneous_2157656933
source ScienceDirect Freedom Collection
subjects Adult
Biomarkers - analysis
Blood Glucose - analysis
Diabetes Mellitus, Type 2 - metabolism
Diabetes Mellitus, Type 2 - prevention & control
diabète de type 2
Disease Management
Female
Follow-Up Studies
Glycated Hemoglobin A - analysis
Humans
Hypoglycemic Agents - therapeutic use
inertie thérapeutique
Male
Medication Adherence - statistics & numerical data
Middle Aged
Needs Assessment
Patient Care - methods
Patient Care - standards
Physicians, Primary Care - standards
Practice Guidelines as Topic - standards
primary care
Prognosis
soins de santé primaires
specialist
Specialization - statistics & numerical data
spécialiste
Surveys and Questionnaires
therapeutic inertia
type 2 diabetes
title Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T20%3A21%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glycated%20Hemoglobin%20Level%20Goal%20Achievement%20in%20Adults%20With%20Type%202%20Diabetes%20in%20Canada:%20Still%20Room%20for%20Improvement&rft.jtitle=Canadian%20journal%20of%20diabetes&rft.au=Leiter,%20Lawrence%20A.&rft.date=2019-08&rft.volume=43&rft.issue=6&rft.spage=384&rft.epage=391&rft.pages=384-391&rft.issn=1499-2671&rft.eissn=2352-3840&rft_id=info:doi/10.1016/j.jcjd.2018.10.005&rft_dat=%3Cproquest_cross%3E2157656933%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c356t-20c492fdfc100a1660f028f0c0a3e977cabf5d0ad7fca931cb2068fb6aa661663%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2157656933&rft_id=info:pmid/30554985&rfr_iscdi=true